NeuroTechnology Investors (NTI)

Radical? Catheter Technologies, an NTI portfolio company, announced its second #FDA 510(k) clearance for the 8F Radical Catheter, expanding therapeutic options in #neurovascular procedures. Co-founder and CEO, Brian Martin, shared, “The 8F clearance, following the success of the 7F, marks a critical milestone toward offering a comprehensive range of sizes and indications for neurovascular procedures.” Martin Dieck, Radical’s Chairman and co-founder, added, “Our clinical experience has been remarkable… We are encouraged by the field performance to date, as highlighted by direct physician feedback… In the coming months, we plan to achieve additional milestones that will expand our platform further and propel us into a full commercial launch.” Adding to this momentum, Radical has opened a state-of-the-art manufacturing facility to facilitate commercial expansion. To read the press release in full, click here: https://bit.ly/4akKabY. At NTI, advancing innovation and the field of #neurosurgery is at the heart of everything we do. Congratulations to the Radical team for driving progress in neurovascular care! #Innovation #Neurotech #NTI

Exciting news in minimally invasive #neurosurgery! E8 is set to transform port-based neurosurgery with a groundbreaking suite of integrated instruments designed for precision and efficiency in emergent and planned procedures. As Martin Dieck, Chairman of E8, Inc., shared: “The Jacobs Institute’s innovation and clinical insight make them the ideal partner to bring transformative technologies to the neurosurgical community and improve patient care.” Game-changing advancements are on the way! #Innovation #Neurotech #NTI #MedicalAdvancements

Kudos to the Synchron team for this remarkable achievement! Synchron’s innovative BCI system offers a minimally invasive approach to restoring communication and autonomy for individuals with severe paralysis. As an early investor, NTI is thrilled to witness this development, supported by Martin Dieck's insightful leadership as Chairman of Synchron’s Board. ? Synchron’s partnership with NVIDIA and integration of the Holoscan platform represents a significant advancement in real-time AI and edge computing for brain-computer interfaces. This collaboration improves neural signal processing, minimizes latency, and establishes a foundation for scalable brain-language models that could revolutionize neuroprosthetics and digital interaction. This milestone promises to drive transformative change in the field! #Innovation #Neurotech

NTI congratulates the EndoStream team on this important milestone and is inspired by the potential of their advancements to improve patient outcomes. At NTI, we are committed to supporting groundbreaking solutions that push the boundaries of medical innovation. As the lead investor in EndoStream Medical, we are proud to be driving innovation and look forward to seeing how this progress continues to shape the future of neurosurgery. J Mocco, MD, NTI Manager and Endostream Board Member, stated, "The clinical success of the Nautilis? and the acquisition of Endostream by Kaneka Corporation is an excellent example of the special value NTI brings to its investment portfolio. NTI's unique position in the neurologic and vascular ecosystems leverages broad connections throughout every aspect of the med-tech space, from strategic relationships to regulatory insight and clinical trial expertise, all of which help its portfolio companies bring meaningful, disruptive technologies to patients. This acquisition is one more example, added to the prior portfolio companies RIST Neurovascular and Neuroradial Technologies acquisitions by Medtronic, of the successful ability of NTI to identify technology that addresses unmet needs, bring intelligent capital to bear, and provide crucial expertise to dramatically accelerate the pathway from concept to clinical utility, ultimately bringing critical solutions to physicians and patients.”? #Innovation #Neurosurgery #NTI #MedicalAdvancements

???We’re on LinkedIn!??? At NeuroTechnology Investors, we’re proud to support a portfolio of innovative companies transforming the future of #neurotechnology and healthcare. Join us as we share insights, breakthroughs, and updates from across our network. We invite all our friends, key opinion leaders, physicians, and industry experts to follow, engage, and connect with us. Your input is essential as we drive advancements and help shape the future of #neurotech. And don’t forget to check out our website???:?https://bit.ly/3XQelSG. #HealthcareInnovation #NeuroScience

As we reflect on 2024, we’re profoundly grateful to be leading the charge in advancing paradigm-shifting #neurointerventional technologies. Together with our portfolio of innovative medtech and biotech companies, we’ve made incredible strides toward transforming the way neurological diseases are approached and potentially treated. The future is bright. 2025 holds the promise of exciting data and pivotal clinical milestones, and we’re energized by the potential to redefine what’s possible in the care of neurological conditions. From all of us at NeuroTechnology Investors, we wish you a joyous holiday season and a new year filled with progress, purpose and innovation. Together, we’re changing lives—one breakthrough at a time. Here’s to an extraordinary year ahead! #NeuroTechnology #HealthcareInnovation #Neuroscience

Neurotechnology Investors (NTI) is proud to highlight the progress of portfolio company FreeOx Biotech, which has achieved a significant step forward in its clinical development program. The company’s lead compound, Ox-01, has been selected by the National Institute of Neurological Disorders and Stroke (NINDS) for inclusion in the StrokeNet Thrombectomy Endovascular Platform (STEP) clinical program. This selection follows a rigorous evaluation through NINDS’ SPAN (Stroke Preclinical Assessment Network) and positions FreeOx to advance toward its Phase 2/3 AURORA trial in 2025. As an adjunctive treatment for Acute Ischemic Stroke (AIS), Ox-01 represents the type of innovative approach that aligns with NTI’s mission to support transformative solutions addressing critical unmet needs. We congratulate the FreeOx team on this milestone and look forward to their continued progress. ? #Stroke #StrokeResearch #FreeOxBiotech #Innovation

It was an honor to showcase the latest advancements in #neurointerventional research and engage in meaningful discussions with top experts in the field. The exchange of ideas and innovations drives NTI forward, and we’re grateful for the opportunity to be a part of it—thank you, #WFITNCongress! #ICYMI: Earlier this month, NTI, alongside Radical Catheter Technologies and Borvo Medical, presented at the 17th World Federation of Interventional and Therapeutic Neuroradiology (WFITN) Congress. NTI’s Founder and CEO, Martin Dieck, provided an insightful overview of our diverse portfolio and detailed our forward-looking approach to interventional and therapeutic solutions. Check out the photos below. To learn more about NTI and our portfolio of innovative companies, click here ??: https://bit.ly/3XQelSG.

Please join us this afternoon for WFITN NEW YORK's MedTech Innovation Sessions, featuring insightful presentations from two of our portfolio companies. Borvo Medical will kick off with today's announcement of FDA 510(k) clearance for its Borvo EVAC System and a discussion on this technology's transformative potential. Next, Dr. Christopher Kellner, MD and Brian Martin will introduce the Radical patented catheter platform, followed by Dr. Adnan Siddiqui, MD, PhD of the Jacobs Institute, who will explore next-generation innovations in neurovascular medtech.

#NEWS: Borvo Medical today announced U.S. FDA 510(k) clearance of its Borvo (Endoport Vacuum Assisted Collection) EVAC? system, an innovative surgical device offering a minimally invasive option for surgical brain treatment. Designed to address the limitations of existing devices, “Borvo EVAC represents a significant advancement in the approach to treating subdural hematoma (SDH),” said Martin Dieck, Founder and CEO of Borvo Medical, a NeuroTechnology Investors (NTI) portfolio company. With an aging population and the rise in usage of blood thinners, SDH drainage cases are expected to rise exponentially. By 2030, over 60,000 SDH procedures are estimated to be performed annually, potentially reaching 140,000 cases per year as the population ages and medical interventions expand. To read the press release in full, click here ??: https://bit.ly/4eFAGJN. #neurotechnology #neurointerventional #MedTechInnovation #WFITN2024